Septerna, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEPN research report →
Companysepterna.com
Septerna, Inc. , a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease.
- CEO
- Jeffrey T. Finer
- IPO
- 2024
- Employees
- 75
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.26B
- P/E
- -34.79
- P/S
- 17.47
- P/B
- 3.31
- EV/EBITDA
- -18.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.42%
- Op Margin
- -77.07%
- Net Margin
- -49.88%
- ROE
- -9.44%
- ROIC
- -11.28%
Growth & Income
- Revenue
- $45.95M · 4174.51%
- Net Income
- $-48,879,000 · 31.92%
- EPS
- $-1.10 · 43.01%
- Op Income
- $-80,797,000
- FCF YoY
- 257.63%
Performance & Tape
- 52W High
- $32.63
- 52W Low
- $8.86
- 50D MA
- $24.87
- 200D MA
- $22.69
- Beta
- 2.20
- Avg Volume
- 340.56K
Get TickerSpark's AI analysis on SEPN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Bhatt Elizabeth | other | 4,000 |
| Apr 15, 26 | Bhatt Elizabeth | sell | 2,573 |
| Apr 15, 26 | Bhatt Elizabeth | sell | 1,101 |
| Apr 15, 26 | Bhatt Elizabeth | sell | 326 |
| Apr 15, 26 | Bhatt Elizabeth | other | 4,000 |
| Mar 2, 26 | Shaikhly Samira | other | 5,101 |
| Mar 2, 26 | Shaikhly Samira | sell | 4,090 |
| Mar 2, 26 | Shaikhly Samira | other | 11,638 |
| Mar 2, 26 | Shaikhly Samira | other | 53,714 |
| Mar 2, 26 | Shaikhly Samira | other | 53,714 |
Our SEPN Coverage
We haven't published any research on SEPN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SEPN Report →